경구 항당뇨병제 시장 보고서(2026년)

Oral antidiabetic drugs are medications taken by mouth to help manage and control blood glucose levels in individuals with type 2 diabetes. These drugs act through various mechanisms, including increasing insulin sensitivity, stimulating insulin secretion, or reducing glucose production in the liver. They play a vital role in diabetes management to prevent complications and support long-term health.

The main drug classes of oral antidiabetic medications include biguanides, dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, sulfonylureas, thiazolidinediones, meglitinides, alpha-glucosidase inhibitors, and others. Biguanides, for example, primarily lower blood glucose by reducing hepatic glucose production and enhancing insulin sensitivity. These drugs are administered via oral, sublingual, or buccal routes and are used in therapeutic areas such as type 2 diabetes, gestational diabetes, and type 1 diabetes. They are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, and serve key end users including hospitals, pharmacy stores, drugstores, diabetes treatment centers, and more.

Tariffs have affected the oral antidiabetic drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and finished products, leading to higher prices for key drug classes like SGLT2 inhibitors and DPP-4 inhibitors. Hospital pharmacies and retail pharmacies in regions such as North America and Asia-Pacific, including India and China, are particularly impacted. While tariffs pose challenges in supply chain and cost management, they also encourage local manufacturing and the development of domestically produced drug formulations, supporting long-term market resilience.

The oral antidiabetic drugs market research report is one of a series of new reports from The Business Research Company that provides oral antidiabetic drugs market statistics, including oral antidiabetic drugs industry global market size, regional shares, competitors with a oral antidiabetic drugs market share, detailed oral antidiabetic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the oral antidiabetic drugs industry. This oral antidiabetic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral antidiabetic drugs market size has grown strongly in recent years. It will grow from $66.73 billion in 2025 to $71.42 billion in 2026 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to limited availability of oral antidiabetic drug classes, reliance on conventional biguanides and sulfonylureas, increasing incidence of type 2 diabetes, growing hospital and pharmacy distribution networks, rising awareness of diabetes management.

The oral antidiabetic drugs market size is expected to see strong growth in the next few years. It will grow to $92.64 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to development of novel dpp-4 inhibitors and sglt2 inhibitors, expansion of combination therapies, increasing adoption of personalized medicine approaches, growth of online pharmacy and telemedicine channels, rising government initiatives for diabetes care. Major trends in the forecast period include rising prevalence of type 2 diabetes, increasing adoption of combination oral antidiabetic drugs, expansion of online and retail pharmacy channels, growing focus on personalized diabetes management, enhanced awareness and education on diabetes care.

The rising prevalence of type 2 diabetes is expected to drive growth in the oral antidiabetic drugs market in the coming years. Type 2 diabetes is a chronic condition in which the body either resists insulin or does not produce enough to maintain normal blood glucose levels. Its increasing prevalence is largely linked to rising obesity rates, as excess body fat contributes to insulin resistance and impaired glucose regulation. Oral antidiabetic drugs help manage type 2 diabetes by enhancing insulin sensitivity, stimulating insulin secretion, or reducing glucose production and absorption, thereby maintaining healthy blood sugar levels. For example, in March 2025, the Office for Health Improvement and Disparities, a UK-based government agency, reported that type 2 diabetes prevalence among adults aged 17 and older in England rose to 7.0%, up from 6.8% in March 2023. This demonstrates that the rising prevalence of type 2 diabetes is fueling the oral antidiabetic drugs market.

Key companies in the oral antidiabetic drugs market are focusing on clinical trials to develop safer and more effective therapies, expand their product offerings, and secure regulatory approvals for next-generation treatments. Clinical trials are controlled studies conducted on human participants to evaluate the safety, efficacy, and side effects of new treatments. For instance, in April 2025, Eli Lilly and Company, a U.S.-based pharmaceutical firm, introduced Orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist, following successful phase 3 trials. This oral therapy is designed to deliver efficacy and safety comparable to injectable options while improving patient adherence. In trials, Orforglipron lowered HbA1c-a key blood sugar marker-by 1.3% to 1.6% across different doses over 40 weeks.

In January 2024, Roche Group, a Switzerland-based pharmaceutical company, acquired Carmot Therapeutics Inc. for an undisclosed sum. Through this acquisition, Roche aimed to enhance its pipeline in diabetes and obesity treatments by leveraging Carmot's innovative small-molecule therapies targeting incretin biology. Carmot Therapeutics, a U.S.-based firm, develops oral antidiabetic drugs, including CT-996, a once-daily oral small-molecule GLP-1 receptor agonist.

Major companies operating in the oral antidiabetic drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, C.H. Boehringer Sohn AG & Co. KG, Viatris Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Cipla Limited

North America was the largest region in the oral antidiabetic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral antidiabetic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral antidiabetic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral antidiabetic drugs market consists of sales of dual or combination oral therapies, glucokinase activators, and amylin analogs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Antidiabetic Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses oral antidiabetic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral antidiabetic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oral antidiabetic drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Biguanides; Dipeptidyl Peptidase-4 Inhibitors; Sodium Glucose Transport Protein -2 Inhibitors; Sulfonylureas; Thiazolidinediones; Megalitinides; Alpha Glucosidase Inhibitors; Other Drug Classes
• 2) By Route Of Administration: Oral; Sublingual; Buccal
• 3) By Therapeutic Area: Type 2 Diabetes; Gestational Diabetes; Type 1 Diabetes
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Channels
• 5) By End User: Hospitals; Pharmact Store; Drug Store; Diabetes Treatment Centers; Other End Users
• Subsegments:
• 1) By Biguanides: Metformin Hydrochloride; Metformin Extended Release; Combination Products
• 2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin; Vildagliptin
• 3) By Sodium Glucose Transport Protein-2 (SGLT2) Inhibitors: Canagliflozin; Dapagliflozin; Empagliflozin; Ertugliflozin
• 4) By Sulfonylureas: Glipizide; Glyburide; Glimepiride; Chlorpropamide; Tolbutamide
• 5) By Thiazolidinediones: Pioglitazone; Rosiglitazone
• 6) By Meglitinides: Repaglinide; Nateglinide
• 7) By Alpha Glucosidase Inhibitors: Acarbose; Miglitol; Voglibose
• 8) By Other Drug Classes: Bromocriptine; Colesevelam
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Bayer AG; Novartis AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Novo Nordisk A/S; C.H. Boehringer Sohn AG & Co. KG; Viatris Inc.; Teva Pharmaceutical Industries Limited; Astellas Pharma Inc.; Sun Pharmaceutical Industries Limited; Cipla Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Oral Antidiabetic Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Oral Antidiabetic Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Oral Antidiabetic Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Oral Antidiabetic Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Artificial Intelligence & Autonomous Intelligence
• 4.2. Major Trends
  • 4.2.1 Rising Prevalence Of Type 2 Diabetes
  • 4.2.2 Increasing Adoption Of Combination Oral Antidiabetic Drugs
  • 4.2.3 Expansion Of Online And Retail Pharmacy Channels
  • 4.2.4 Growing Focus On Personalized Diabetes Management
  • 4.2.5 Enhanced Awareness And Education On Diabetes Care

5. Oral Antidiabetic Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Pharmacy Stores
• 5.3 Retail Pharmacies
• 5.4 Diabetes Treatment Centers
• 5.5 Clinics And Healthcare Facilities

6. Oral Antidiabetic Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Oral Antidiabetic Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Oral Antidiabetic Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Oral Antidiabetic Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Oral Antidiabetic Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Oral Antidiabetic Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Oral Antidiabetic Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Oral Antidiabetic Drugs Market Segmentation

• 9.1. Global Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Sodium Glucose Transport Protein -2 Inhibitors, Sulfonylureas, Thiazolidinediones, Megalitinides, Alpha Glucosidase Inhibitors, Other Drug Classes
• 9.2. Global Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Sublingual, Buccal
• 9.3. Global Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Type 2 Diabetes, Gestational Diabetes, Type 1 Diabetes
• 9.4. Global Oral Antidiabetic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Channels
• 9.5. Global Oral Antidiabetic Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Pharmact Store, Drug Store, Diabetes Treatment Centers, Other End Users
• 9.6. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Biguanides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Metformin Hydrochloride, Metformin Extended Release, Combination Products
• 9.7. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin
• 9.8. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Sodium Glucose Transport Protein-2 (SGLT2) Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin
• 9.9. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide
• 9.10. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Thiazolidinediones, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pioglitazone, Rosiglitazone
• 9.11. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Meglitinides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Repaglinide, Nateglinide
• 9.12. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Alpha Glucosidase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Acarbose, Miglitol, Voglibose
• 9.13. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Bromocriptine, Colesevelam

10. Oral Antidiabetic Drugs Market Regional And Country Analysis

• 10.1. Global Oral Antidiabetic Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Oral Antidiabetic Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Oral Antidiabetic Drugs Market

• 11.1. Asia-Pacific Oral Antidiabetic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Oral Antidiabetic Drugs Market

• 12.1. China Oral Antidiabetic Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Oral Antidiabetic Drugs Market

• 13.1. India Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Oral Antidiabetic Drugs Market

• 14.1. Japan Oral Antidiabetic Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Oral Antidiabetic Drugs Market

• 15.1. Australia Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Oral Antidiabetic Drugs Market

• 16.1. Indonesia Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Oral Antidiabetic Drugs Market

• 17.1. South Korea Oral Antidiabetic Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Oral Antidiabetic Drugs Market

• 18.1. Taiwan Oral Antidiabetic Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Oral Antidiabetic Drugs Market

• 19.1. South East Asia Oral Antidiabetic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Oral Antidiabetic Drugs Market

• 20.1. Western Europe Oral Antidiabetic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Oral Antidiabetic Drugs Market

• 21.1. UK Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Oral Antidiabetic Drugs Market

• 22.1. Germany Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Oral Antidiabetic Drugs Market

• 23.1. France Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Oral Antidiabetic Drugs Market

• 24.1. Italy Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Oral Antidiabetic Drugs Market

• 25.1. Spain Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Oral Antidiabetic Drugs Market

• 26.1. Eastern Europe Oral Antidiabetic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Oral Antidiabetic Drugs Market

• 27.1. Russia Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Oral Antidiabetic Drugs Market

• 28.1. North America Oral Antidiabetic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Oral Antidiabetic Drugs Market

• 29.1. USA Oral Antidiabetic Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Oral Antidiabetic Drugs Market

• 30.1. Canada Oral Antidiabetic Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Oral Antidiabetic Drugs Market

• 31.1. South America Oral Antidiabetic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Oral Antidiabetic Drugs Market

• 32.1. Brazil Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Oral Antidiabetic Drugs Market

• 33.1. Middle East Oral Antidiabetic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Oral Antidiabetic Drugs Market

• 34.1. Africa Oral Antidiabetic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Oral Antidiabetic Drugs Market Regulatory and Investment Landscape

36. Oral Antidiabetic Drugs Market Competitive Landscape And Company Profiles

• 36.1. Oral Antidiabetic Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Oral Antidiabetic Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Oral Antidiabetic Drugs Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

37. Oral Antidiabetic Drugs Market Other Major And Innovative Companies

• Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, C.H. Boehringer Sohn AG & Co. KG, Viatris Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Cipla Limited

38. Global Oral Antidiabetic Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Oral Antidiabetic Drugs Market

40. Oral Antidiabetic Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Oral Antidiabetic Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Oral Antidiabetic Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Oral Antidiabetic Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer